


Quinagolide treatment reduces invasive and angiogenic properties of Endometrial Mesenchymal Stromal Cells

Corinne Iampietro^{1*}, Alessia Brossa^{1*}, Stefano Canosa², Stefania Tritta¹, Glenn E Croston³, Torsten M. Reinheimer⁴, Filippo Bonelli¹, Andrea Carosso², Gianluca Gennarelli², Stefano Cosma², Chiara Benedetto², Alberto Revelli², Benedetta Bussolati^{1§}

SUPPLEMENTARY DATA

Supplementary Figure S1



Supplementary Figure S1. Phenotype of GFP⁺ HUVECs and effect of quinagolide on VEGF-A expression by EMSC-HUVEC coculture. **A:** Representative flow cytometry analysis of HUVEC GFP⁺ cells, showing the expression of GFP and the typical HUVEC markers (CD146, CD29, CD105, CD31, VEGFR1, VEGFR2, VEGFR3 and TIE2). **B:** Real time PCR analysis showing the relative quantification (RQ) of VEGF-A in HUVECs, EMSCs at basal levels and after 48 h co-culture with HUVECs (Coculture, CTL), treated for 24 h or 48 h with 100 nM quinagolide (Q100nM 24h and Q100nM 48h, respectively). No significant effect of quinagolide was observed. Data are expressed as mean \pm SD of VEGF-A RQ, normalized to GAPDH and to CTL, of three independent experiments, performed on different EMSC lines. A-Nova was performed: **= $p < 0.001$ respect to CTL.